- Home
- SLGL
as 12-20-2024 4:00pm EST
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
| Founded: | 1997 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 18.3M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 53.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $1.57 | Next Earning Date: | 11-15-2024 |
| Revenue: | $11,707,000 | Revenue Growth: | 869.93% |
| Revenue Growth (this year): | 500.51% | Revenue Growth (next year): | -8.30% |
Latest Sol-Gel Technologies Ltd. News
SLGL Breaking Stock News: Dive into SLGL Ticker-Specific Updates for Smart Investing
Zacks
a month ago
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
MT Newswires
a month ago
Sol-Gel's Receives Nasdaq Extension to Regain Compliance With Nasdaq Rule
GlobeNewswire
a month ago
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Simply Wall St.
a month ago
Sol-Gel Technologies Third Quarter 2024 Earnings: Beats Expectations
Zacks
a month ago
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Zacks
3 months ago
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks
4 months ago
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
Compare SLGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLGL Sol-Gel Technologies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.